Once-per-week selinexor, Bortezomib, and dexamethasone vs. twice per-week Bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial - Grosicki, S; Simonova, M; Spicka, I (Lancet, 2020)